Ipca Laboratories Ltd reports Q2 FY27 consolidated revenue of ₹2,909.94 crore, up 14% YoY, and attributable profit of ₹375.13 crore, up 33%
- Consolidated EBITDA margin rose to 22.97% from 21.68% a year earlier; revenue increased 4.4% sequentially and profit rose 32.8%.
- Standalone revenue was ₹2,255.61 crore, up 17% YoY; net profit rose 27% to ₹387.29 crore, with EBITDA margin at 26.61% versus 25.46%.
- Consolidated results include a ₹24.26 crore exceptional provision for a legal claim; statutory auditors issued unmodified limited-review conclusions.
